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Abstract 
Using an ovariectomised (OVX) ovine model, we provide an analysis of the timing of 
changes in bone following estrogen deficiency. The expression of genes known to regulate 
osteoclastogenesis, matrix production and mineralisation, as measured by real time RT-PCR, 
were all significantly increased by 12 months and increased expression was maintained 
through to 31 months post-OVX, compared to controls. FTIR spectroscopy confirmed that 
mineralised crystals were less mature than in controls 12 months post-OVX, and were even 
less so by 31 months. The mineral-to-matrix ratio was significantly reduced by 31 months 
while the ratio of mature to immature collagen cross-linking was initially increased at 12 
months and subsequently reduced 31 months post-OVX. In contrast, trabecular number, 
thickness and separation were unchanged at 12 months. Significant reductions in the 
trabecular number and thickness and a significant increase in trabecular separation were 
observed 31 months after OVX. Most notably perhaps, these combined changes led to a 
significant reduction in the compressive strength of the trabecular bone after 31 months. The 
results indicate that there is an initial increase in bone turnover, which is accompanied by a 
change in bone composition. This is followed by a continued increase in bone resorption and 
relative reduction in bone formation, leading to deterioration in bone micro-architecture. 
Ultimately, these cumulative changes led to a significant reduction in the compressive 
strength of bones following 31 months of estrogen deficiency. These findings provide an 
important insight into the time sequence of changes during osteoporosis. 
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Introduction 
Postmenopausal osteoporosis is often referred to as high-turnover osteoporosis and occurs in 
women following menopause due to a decrease in estrogens [1]. Typically osteoporosis 
results in a thinning of the trabecular network, which leads to a reduction in bone volume 
fraction, increased trabecular separation and decreased trabecular number. These changes in 
architecture are instrumental in bringing about the significant reduction in bone strength, 
which is seen in osteoporosis. It has been shown that measures of bone architecture can 
explain a statistically significant proportion of the variability in bone strength [2].  
A comprehensive study of bone from premenopausal, osteopenic and osteoporotic women 
found that trabecular bone volume fraction, trabecular number and trabecular thickness were 
reduced in osteopenic women compared to premenopausal women and these values 
continued to reduce in the osteoporotic group [3]. These changes have been explained by 
studying cytokines and growth factors that regulate bone cell activity during bone 
remodelling and osteoporosis. The receptor activator of nuclear factor Kappa B ligand 
(RANKL) and osteoprotegerin (OPG) produced by osteoblasts are dominant factors in 
osteoclastogenesis that lead to bone resorption [4].  
The macro-scale biomechanical properties of bone have predominantly been shown to be 
reduced in osteoporotic bone. However, studies have shown that during estrogen deficiency, 
the yield strength and elastic modulus at the tissue level is increased relative to controls in an 
ovariectomised rat model of osteoporosis [5]. There is evidence that a change in the 
composition of the bone tissue occurs during estrogen deficiency. Studies have shown that 
estrogen deficiency reduces the mean bone mineral density [6, 7] while others have shown an 
increase in mineralisation [5]. Interestingly a recent study showed the distribution of tissue 
level mineral is more heterogeneous in osteoporotic femurs and also that these changes are 
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anatomically distinct and do not occur uniformly throughout the proximal femur [8]. In 
addition to changes in mineral, osteoporosis is accompanied by increased turnover of 
collagen and is associated with an overall reduction in the amount of type I collagen present 
in bone tissue [9, 10]. It has also been proposed that a polymorphism of the COLIα1 gene 
plays a role in the increased risk of fragility fracture during osteoporosis [11]. There are also 
reports that collagen cross-links may play an important role in determining fracture risk in 
aging and osteoporosis [12].   
Osteoblasts are responsible for the production of non-collagenous proteins (NCP), such as 
osteocalcin (OCN) and osteopontin (OPN). Due to their high affinity for calcium phosphate 
during mineralisation, NCPs play a role in bone matrix organisation by acting as binding 
proteins and thereby act as mineral crystal nucleation sites on the organic matrix [13-16], but 
they also facilitate cell attachment during bone turnover [17]. However, there are little data in 
the literature on the effect of osteoporosis or estrogen deficiency on NCPs. That which does 
exist is conflicting as NCP content has been shown to be considerably reduced in 
osteoporotic bone when compared with age-matched or young controls [18], while other 
studies have reported that the levels of osteocalcin are increased following estrogen 
deficiency [19]. 
The objective of this study is to provide a comprehensive analysis of the timing of changes in 
bone microarchitecture, gene expression, composition of bone matrix, and mechanical 
properties of bone from estrogen-deficient animals. Specifically, trabecular microarchitecture 
was quantified by micro computed tomography 12 and 31 months post-ovariectomy. The 
expression of proteins known to regulate osteoclastogenesis (RANKL, osteoprotegerin, 
osteopontin), matrix production (COL1α1, COL1α2) and mineralisation (osteocalcin) were 
measured using real-time RT-PCR. FTIR spectroscopy analysis of matrix composition, 
including mineralisation and collagen cross-linking, was performed to determine how 
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changes in gene expression manifest themselves within the matrix. Finally, bone strength was 
measured to quantify the cumulative effect of these architectural and compositional changes 
on fracture susceptibility. 
Materials and Methods 
Animal Study 
All animals were cared for in accordance with the Guide for the Care and Use of Laboratory 
Animals. Nineteen skeletally mature (> 4 years), mixed-breed ewes were randomly assigned 
into an ovariectomy (OVX, n=14) or control group (control, n=5) on which no OVX 
procedure was carried out. All procedures were carried out following institutional ethical 
approval and under an animal licence granted by the Irish Department of Health (B100/2443). 
Ovariectomy was performed through a ventral midline laparotomy under general anaesthesia 
with sodium thiopentone (Pentanol, Abbot Ltd, Sligo, Ireland) and maintained on 3-4% 
halothane (Merial Animal Health, Harlow, UK) in oxygen. Twelve months post-operatively, 
half of the ovariectomy group were sacrificed along with the 5 control animals. All remaining 
animals were sacrificed 31 months post-OVX.  
Micro Computed Tomography (µCT) 
A cylinder of trabecular bone was extracted from the left proximal femur of each animal 
using a diamond tipped coring tool (Cajero Ltd, Kent, UK). A specimen 7mm in diameter and 
20mm in length was removed in the coronal plane from the fovea to the greater trochanter. 
To minimise deterioration of the bone over the duration of this study, all samples had 
minimal room temperature exposure and were stored in saline upon removal from the freezer 
prior to testing.  
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Trabecular microarchitecture at the proximal femur was analysed by µCT (µCT40, Scanco, 
Switzerland). The cylinders were wrapped in saline soaked gauze to ensure they remained 
hydrated during scanning. The scans were performed at a resolution of 8µm, at 70kVp and 
114µA. A threshold value of 210 was selected based on the ability to adequately discriminate 
between bone and the other components present in the sample, i.e. air and marrow. Bone 
volume fraction (BV/TV), trabecular number (Tb.N. [mm
-1
]), trabecular thickness (Tb.Th. 
[mm]) and trabecular separation (Tb.Sp. [mm]) were then quantified from the 3-dimensional 
reconstruction of the cylinder [20]. In calculating these parameters the cylinder was reduced 
by 1mm in diameter to allow for the build up of bone dust and fragments that were produced 
during the coring procedure. 
 
Mechanical Testing 
Following µCT scanning, the cylinders were press fitted into brass endcaps and these were 
attached to steel platens. Taking in to consideration the depth of the endcaps, the dimensions 
of the cylinder (7mm in diameter and 20mm in length) were based on the work of Keaveny et 
al who recommended that cylinders of trabecular bone for unixial compression testing should 
have an effective gauge length to diameter ratio of 2:1 [21].  The samples were loaded in a 
servo-hydraulic materials testing machine (Instron, Bucks, UK) at a rate of 1mm/min using 
displacement control. Five preconditioning loads of 20N were applied before the cylinders 
were compressed to failure. The data were logged and plotted as a load-displacement curve. 
Calculation of the ultimate compressive strength was determined taking into consideration 
the effect of side artefacts, the concept that trabeculae around the perimeter are not attached 
at both ends and therefore do not contribute to the overall strength of the sample and should 
not be considered [22].  
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Real time Reverse Transcription Polymerase Chain Reaction (Real time RT-PCR) 
Immediately following sacrifice, the right metacarpal of each sheep was snap frozen in liquid 
nitrogen and stored at -80
0
C prior to processing. On removal from the freezer the bone was 
initially cut into small fragments using a diamond saw (Struers, Germany) before grinding to 
a powder in a freezer mill (Spex Sample Prep 6750 Freezer Mill).  
A sample of the powdered bone was placed in denaturation solution (Totally RNA Kit, 
Ambion) before the ribonucleic acid (RNA) was extracted using the phenol chloroform 
method, as per the manufacturer’s instructions, with the addition of glycogen (Ambion) to 
enhance RNA yield and aid recovery of the pellet. RNA concentration and purity (260/280 
absorbance ratio) were determined using an atomic absorption spectrophotometer (Wallac 
Victor, PerkinElmer Life Sciences). Total RNA prepared using this method was found to be 
of sufficient quality to be used directly for real time reverse transcription polymerase chain 
reaction.  
First-strand cDNA (complementary deoxyribonucleic acid) synthesis was performed with 1 
µg total RNA (ribonucleic acid) from each sample, using a first-strand cDNA synthesis kit 
with Superscript III (Invitrogen; Carlsbad, CA, USA) and 250ng random hexamer primer 
(Geneworks, Adelaide, SA, Australia), in accordance with the manufacturer's instructions. 
RANKL, OPG, COL1A1, COL1A2, OCN, OPN and glyceraldehyde phosphate 
dehydrogenase (GAPDH) mRNA expression were analysed by real time RT-PCR, using 
BioRad iQ SYBR Green Supermix (BioRad, Hercules, CA, USA) on a Rotor-Gene 
thermocycler (Corbett Research, Mortlake, NSW, Australia). The reactions were incubated at 
94°C for 10 minutes for one cycle, and then 94°C (15 seconds), 60°C (30 seconds) and 72°C 
(30 seconds) for 45 cycles. All real time RT-PCRs were validated by the presence of a single 
peak in the melt curve analysis.  
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Two samples from each animal was analysed and real time RT-PCR reactions were carried 
out in triplicate for each sample. Relative levels of mRNA expression of the gene of interest 
between samples were quantified using the comparative cycle threshold (CT) method. Briefly, 
the formula XN = 2
-∆C
T was used, where XN is the relative amount of target gene in question 
and ∆CT is the difference between the CT of the gene in question and the CT of the 
housekeeping gene, GAPDH, for a given sample. 
Fourier Transform Infrared (FTIR) Spectroscopy  
Powdered bone was added to potassium bromide and ground together in a mortar with a 
pestle. The powder was placed in a mould and compressed in a press at 10 tonnes to form a 
transparent specimen disc. The disc was placed into a Bruker Tensor 27 FTIR machine 
(Bruker Optik GmbH) and spectra obtained at a resolution of 4 cm
-1
 from 4000 to 400 cm
-1
. 
One powdered bone sample per animal was assessed and each spectrum was an average of 20 
scans. On each spectrum the mineral-to-matrix ratio was assessed as the ratio of the area of 
the phosphate band to the area of the Amide I band. Crystallinity was calculated as the peak 
area of sub-bands at 1030 and 1020cm
-1
. Collagen cross-linking (XLR) was calculated as the 
intensity ratio of sub-bands at 1660cm
-1
, representing pyridinoline (PYD or mature) cross-
links, and 1690cm
-1
 representing dehydro-dihydroxylysinonorleucine (deH-DHLNL or 
immature) cross-links. 
Statistics 
Results are presented as mean ± standard deviation. To determine whether ovariectomy 
significantly altered the mRNA expression of bone turnover markers, a fully nested ANOVA 
was used (Minitab
®
 Statistical Software). This analysis took into account the repeated 
measures made on each sample and the multiple samples analysed per animal. For the FTIR, 
µCT and mechanical testing data, results were tested for normality using the SPSS software 
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package (SPSS Inc, Chicago, IL). ANOVA was used to determine statistical significance. A 
p-value of ≤ 0.05 was considered to be significant unless otherwise stated.  
Results 
Effects of Estrogen Deficiency on Trabecular Micro-architecture  
Measurement of trabecular bone micro-architecture using µCT found that bone volume 
fraction (BV/TV) was significantly reduced following 12 and 31 months of estrogen 
deficiency (p ≤ 0.05) (Figure 1). However there were no significant changes in Tb.Sp, Tb.N 
or Tb.Th after 12 months. Significant changes in these parameters were not seen until thirty-
one months post-OVX at which point there was an increase in Tb.Sp. and a reduction in 
Tb.N. and Tb.Th. (p ≤ 0.05). 
Effects of Estrogen Deficiency on Gene Expression 
The mRNA expression of each protein was normalised to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) mRNA and expressed relative to the 12 month controls. 
RANKL:OPG ratio was significantly increased relative to controls after 12  (p ≤ 0.05) and 31 
months of estrogen deficiency following OVX (p ≤ 0.0001) (Figure 2). Longer term (31 
months) estrogen deficiency resulted in an increase in RANKL:OPG mRNA expression 
relative to 12 months of estrogen deficiency (p ≤ 0.005).   
Estrogen deficiency following OVX produced a significant increase in COL1α1 expression at 
both 12 and 31 months (p ≤0.001) relative to control animals (Figure 3). COL1α2 expression 
was also significantly increased in the estrogen-deficient animals at 12 (p ≤ 0.005) and 31 
months post-OVX (p ≤ 0.05) relative to the control. Notably, expression of COL1α2 was 
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significantly reduced in the 31 month group compared to 12 months of estrogen deficiency (p 
≤ 0.005).  
Osteopontin expression was significantly increased following estrogen deficiency (p ≤ 0.001) 
relative to control animals at both time points (Figure 4). However, no significant difference 
was found between the estrogen deficient groups. Osteocalcin expression was also 
significantly increased with estrogen deficiency at 12 (p ≤ 0.05) and 31 months (p ≤ 0.001). It 
was found to be significantly higher in the 31 month deficiency group compared to the 12 
month deficiency group (p ≤ 0.001). 
Effects of Estrogen Deficiency on Matrix Composition 
FTIR analysis found that crystallinity, or mineral maturity, was significantly reduced 
following 12 (p ≤ 0.01) and 31 (p ≤ 0.005) months of estrogen deficiency (Figure 5). 
Comparison between the two time points showed no difference in mineral maturity. Mineral 
to matrix ratio was not significantly reduced after 12 months of estrogen deficiency (p=0.1), 
however, a significant reduction was seen after 31 months (p ≤ 0.05). Collagen cross-linking 
was significantly increased 12 months post-ovariectomy (p ≤0.05) and then reduced to 
control levels after 31 months.   
Effects of Estrogen Deficiency on Bone Strength 
Static compression testing of the femoral trabecular bone cores showed no significant change 
in strength after 12 months of estrogen deficiency. However, a significant reduction in the 
compressive strength was seen after 31 months of estrogen deficiency (p ≤ 0.05) (Figure 6).  
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Discussion 
This study used an ovine model of post menopausal osteoporosis to examine whether 
estrogen deficiency produces significant changes in bone matrix composition prior to, or 
subsequent to, significant changes in architecture and strength. We report for the first time 
that gene expression of markers for osteoclastogenesis, osteoblastogenesis and matrix 
constituents were all significantly changed at the earliest measured time point of 12 months 
post-OVX. Furthermore significant changes in the mineralised crystal maturity, mineral-to-
matrix ratio and collagen cross-linking were detected at 12 months. These changes preceded 
significant architectural changes which did not occur until the later time point of 31 months 
post-OVX. Most notably perhaps, these combined changes led to a significant reduction in 
the compressive strength of the bones at 31 months following estrogen deficiency.   
The involvement of estrogen in the prevention of osteoporosis and the maintenance of 
appropriate bone turnover in men and women has been well established [23, 24]. In early 
postmenopausal women and ovariectomised rats, estrogen withdrawal is associated with 
increased bone turnover in which resorption predominates over bone formation [25-27]. The 
production of the pro-osteoclastogenetic cytokine RANKL, by osteoblasts, is enhanced in 
estrogen deficiency [28] while OPG inhibits the maturation of osteoclasts [29]. In the current 
study, estrogen deficiency resulted in a significant increase in osteoclastogenesis as measured 
by RANKL:OPG expression ratio. Interestingly osteoclastogenesis was significantly greater 
after thirty-one months than after twelve months indicating increased bone resorption over 
time.  
Collagen type I is the most abundant collagen found in the human body and is the main 
organic substance found in bone. At a molecular level, it is composed of a triple helix of two 
α1(1) chains and one α2(1) chain, which are encoded by COL1α1 and COL1α2 genes 
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respectively [30]. The current study found that estrogen deficiency was associated with 
elevated COL1α1 and COL1α2 expression, which is consistent with the increased collagen 
type I production seen previously [31].  However, the data presented here then show reduced 
collagen formation after thirty-one months relative to twelve months of estrogen deficiency. 
Unlike the RANKL:OPG data, which show bone resorption continuing to increase at the later 
time point, this result suggests that bone formation is slowing down over time. It is this 
combined effect of increased resorption and reduced formation that leads to the change in 
architecture in the estrogen deficient animals at thirty-one months.  
It has been reported that synthesis of 10–15% homotrimers of α1, due to a polymorphism in 
the gene, may contribute to osteoporosis [32]. This results in collagen being formed, which 
no longer has the 2:1 ratio of α1(1): α2(1), rather there is an excess of α1(1) chains being 
synthesised and incorporated into the collagen molecule. In the current study the ratio of 
COL1α1:COL1α2 expression in the control group was 0.9 which is similar to levels 
measured in human studies previously [33]. Twelve months post-ovariectomy, this ratio had 
increased significantly to 610 and thirty–one months following ovariectomy this ratio had 
almost doubled to 1100. Previously it has been demonstrated using osteoblast-like cells that 
COL1α2 expression did not vary when cells were exposed to a mineralising media, whereas 
COL1α1 expression, which was initially high, progressively declined, leading to a decrease in 
the COL1α1:COL1α2 ratio concomitant with an increase in mineralisation [34]. The current 
study found that an increase in the COL1α1:COL1α2 ratio is associated with a reduction in 
mineralisation in the metacarpal bone. Our data also indicates that the variation in the 
COL1α1:COL1α2 was mostly attributable to elevated COL1α1 expression, as COL1α2 levels 
did not increase to the same extent following estrogen deficiency. This work suggests that 
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estrogen deficiency results in an over-expression of COL1α1 producing collagen, which is 
structurally, and potentially functionally, different from healthy type I collagen.   
Another interesting result from this study was the increase in the ratio of mature collagen 
cross-links to immature after twelve months of estrogen deficiency followed by a reduction 
after thirty-one months. Using FTIR, collagen cross-linking (XLR) is calculated as the 
intensity ratio of pyridinoline (PYD or mature) cross-links to dehydro-
dihydroxylysinonorleucine (deH-DHLNL or immature) cross-links. Newly formed collagen 
allows immature cross-links to form, resulting in a higher proportion of immature cross-links 
to mature cross- links [12]. As bone formation is high at twelve months a large number of 
immature cross-links are formed, over time these can convert to mature cross-links thus 
shifting the balance at the later time point. This shift in the ratio of mature to immature cross-
links again poses an important question as to the quality of the collagen produced during 
estrogen deficiency.  Further investigation of this and the partners of collagen that regulate 
collagen fibril structure, such as the small proteoglycans biglycan and decorin, are warranted.  
There are conflicting data in the literature on mineralisation and mineral content during 
osteoporosis. Some studies have reported that mineral content is decreased [35, 36] while 
others have shown an increase [5, 37, 38]. The current study found no significant reduction in 
mineral-to-matrix ratio at twelve months although a strong downward trend was evident 
(p=0.1) however, by thirty-one months this reduction in ratio had reached statistical 
significance. This result supports previous work on this animal cohort which has shown 
through the use of quantitative backscatter electron imaging that mineral content is reduced 
following estrogen deficiency in the femur [6, 7]. However, another study has showed that 
changes do not occur ubiquitously throughout the proximal femur [8]. In the current study the 
twelve month estrogen deficient group also showed reduced crystallinity indicative of the 
increased turnover, which is confirmed by the gene expression data presented and previous 
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work on these animals [39]. In addition Figure 7 provides epifluorescence histological 
micrographs confirming the increased turnover in the ovariectomised group relative to the 
controls. After thirty-one months, crystallinity is unchanged, remaining lower than in the 
controls. This indicates a slowing down of bone turnover at the thirty-one month time point, 
which again we have previously seen in this same cohort of animals  [40]. This is also 
consistent with the reduced bone formation as seen with the collagen gene expression data. 
Along with a reduced mineral content, these data indicate that the mineral, which is present 
following estrogen deficiency, is less crystalline than that found in healthy bone.  
An interesting observation of this study is in the quantification of the changes in non-
collagenous protein expression. Osteopontin is a protein that preferentially accumulates at 
mineralised tissue interfaces [41] and plays an important role in regulating osteoclastogenesis 
and is thereby often used as an indicator of bone turnover [42]. One recent study has 
suggested that over-expression of osteopontin is a risk factor for osteoporosis [43] and bone 
loss is suppressed in OPN-deficient mice following ovariectomy, despite an increase in 
osteoclastogenesis [44]. In the current study, we show for the first time that estrogen 
deficiency induced an increase in osteopontin expression which remained elevated over time 
and that these changes occurred prior to significant changes in bone microarchitecture.    
In addition to being associated with increased mineralisation, osteocalcin is a terminal marker 
of osteoblast differentiation which delays crystal nucleation [45]. As such it has been 
suggested to play an inhibitory role during bone formation [46]. In the current study there 
was an approximate 10-fold increase in osteocalcin expression twelve months post-OVX 
while expression in the thirty-one month OVX group was almost 150 times that of the 
controls. As we have shown, bone formation is reduced by thirty-one months and this may 
indeed be as a result of the increased osteocalcin expression seen at this time point.   
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Another notable observation is that the expressions of the selected candidate genes was 
significantly altered after just twelve months of estrogen deficiency, and also coincided with 
changes in the mineral and matrix phases. In contrast to this, significant changes in trabecular 
number, thickness and separation were only detected after thirty-one months, and most 
interestingly these changes were accompanied by a significant reduction in the compressive 
strength of trabecular cores. While bone volume fraction was reduced twelve months post-
OVX, this was likely due to the combined effects of non-significant reductions in trabecular 
number and thickness and increased separation. Mechanical strength was not altered at 
twelve months, thereby showing that although changes in bone composition precede bone 
architecture, these changes were insufficient to significantly reduce the mechanical properties 
of the bone.  
One of the limitations of this study was the lack of a day 0 time point which would have 
allowed a direct comparison of changes over time. However, ethical constraints did not allow 
for the sacrifice of a group of animals at day 0. It must be noted that this study sought to 
understand the effects of estrogen deficiency over time rather than changes due to seasonal 
variation or age. However, we acknowledge that seasonal variation is a limitation of the ovine 
model.  Ovariectomy procedures were carried out in November, when estrogen production is 
naturally at its highest. Therefore, in the absence of a Day 0 group, 12 month controls were 
used for comparison to both 12 month and 31 month OVX animals as these animals were 
sacrificed at the same time of year as the ovariectomy operations were performed. Another 
limitation of this study was the fact real time RT-PCR and FTIR were performed on compact 
bone samples from the metacarpal while µCT was performed on the proximal femur. While 
this is a drawback, the µCT data do show that estrogen deficiency is having a deleterious 
effect on the skeleton and thus proves the efficacy of the OVX sheep model. Therefore, the 
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data obtained from the total mRNA and on mineral and matrix composition can be assumed 
to represent changes in bone following estrogen deficiency. In this, and other studies from the 
group, we have shown increased bone turnover following estrogen deficiency in the ovine 
model at a gene expression level and also using histology. However, we acknowledge that a 
clinical measure of bone turnover would have been an interesting addition to this study. 
In conclusion, this study provides new insights into the sequence of changes that occurs in 
bone following estrogen deficiency.  The results indicate that there is an initial increase in 
both bone resorption and formation i.e. an increase in bone turnover, which is accompanied 
by a change in bone composition. This is followed by a continued increase in bone resorption 
and a relative reduction in bone formation, which leads to a deterioration in the bone micro-
architecture. Ultimately, these cumulative changes led to a significant reduction in the 
compressive strength of the bones 31 months following estrogen deficiency. These findings 
provide an important insight into the time sequence of changes during osteoporosis. 
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Fig. 1: Bone volume fraction (BV/TV) was significantly reduced following estrogen deficiency (a). Trabecular 
number and thickness (c and d) were significantly reduced after 31 months of estrogen deficiency and there 
was a significant reduction in trabecular thickness (b) at this time (The level of significance denotes 
difference from the control group: #, p ≤ 0.05)  
174x163mm (150 x 150 DPI)  
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Fig. 2: RANKL:OPG mRNA expression was increased after 12  and 31 months of estrogen deficiency. 
Estrogen deficiency results in a continued increase in RANKL:OPG ratio over time (The level of significance 
denotes difference from the control group: #, p ≤ 0.05; *, p ≤ 0.0001: difference from 12 months OVX: **, 
p ≤ 0.005)  
61x75mm (150 x 150 DPI)  
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Fig. 3: COL1α1 (a) and COL1α2 (b) mRNA expression levels were both significantly increased following 
estrogen deficiency.  The COL1α1: COL1α2 ratio was also significantly increased following estrogen 
deficiency. (The level of significance denotes difference from the control group for COL1 α 1; #, p ≤0.005: 
difference from control for COL1 α 2; #, p ≤ 0.005; *, p ≤ 0.05: difference from 12 month OVX; **, p ≤ 
0.05; difference from control for COL1α1: COL1α2; #, p ≤0.005)  
231x82mm (150 x 150 DPI)  
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Fig. 4: Both OPN (a) and OCN (b) mRNA expression (relative to GAPDH) were significantly increased 
following estrogen deficiency. (The level of significance denotes difference from the control group in OPN: A, 
p ≤ 0.001: in OCN difference from control: #, p ≤ 0.05: *, p ≤ 0.001: difference from 12 months OVX: **, 
p ≤ 0.001)  
137x69mm (150 x 150 DPI)  
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Fig. 5: FTIR spectroscopy found no significant difference in mineral to matrix ratio (a) after 12 months of 
estrogen deficiency, however, there was a significant reduction after 31 months. Mineral maturity was found 
to be significantly reduced following estrogen deficiency in both groups (b). Collagen crosslinking (c) was 
significantly increased after 12 months of estrogen deficiency before falling again (The level of significance 
denotes difference from the control group in Mineral-to-Matrix ratio: #, p ≤ 0.05: in Crystallinity, *, p ≤ 
0.01, **, p ≤ 0.005: in XLR, #, p ≤ 0.05)  
207x161mm (150 x 150 DPI)  
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Fig. 6: The compressive strength of trabecular bone following 31 months of estrogen deficiency was 
significantly reduced (The level of significance denotes difference from the control group: #, p ≤ 0.05)  
90x95mm (150 x 150 DPI)  
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Fig. 7: Transverse cross section of a metacarpal bone viewed under ultra-violet epifluorescence microscopy 
at X10 magnification. Intravenous fluorochrome markers (Calcein, calcein blue, oxytetracycline, xylenol 
orange and alizarin complexone) were injected into the animals over the duration of the experiment, these 
markers labelled sites of new bone formation. High levels of bone turnover are visible after 12 months in (a) 
OVX bone while low levels are seen in (b) control bone. Histological data on these animals can be found in 
previous studies from our group [39, 40].  
198x99mm (47 x 40 DPI)  
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